A team of Melbourne scientists has been backed by the Australian Government’s Medical Research Future Fund Stem Cell Therapies Mission to support their development of potential new medicines to treat dementia.

Radiopharm Theranostics (ASX:RAD) has achieved a milestone in its ongoing clinical development program for its radiotherapeutic asset, 177Lu-RAD204.

Clinical-stage company Tryptamine Therapeutics (ASX:TYP) has announced the appointment of Herwig Janssen as its non-executive chairman.

OncoSil Medical managing director and CEO Nigel Lange said, “The results of this important analysis highlight the superiority of the OncoSil device compared to Stereotactic Body Radiation Therapy, which is considered to be the best available system for delivering external beam radiotherapy to patients with locally advanced pancreatic cancer."

Percheron Therapeutics (ASX:PER) has lodged a prospectus for a pro-rata non-renounceable bonus offer of unquoted options to acquire loyalty options to eligible shareholders.

Neuren Pharmaceuticals (ASX:NEU) has updated investors on the first quarter 2025 financial results announcement and conference call of its partner Acadia Pharmaceuticals.

Algorae Pharmaceuticals (ASX:1AI) has agreed with the Victorian Centre for Functional Genomics at Peter MacCallum Cancer Centre to validate AI-predicted drug synergies through high-throughput screening.

LTR Pharma (ASX:LTP) has entered a collaborative development agreement with Strategic Drug Solutions to co-develop OROFLOW, a novel intranasal spray targeting Oesophageal Motility Disorders.

AusBiotech CEO Rebekah Cassidy said the investor-focused event will help accelerate the delivery of real-world, home-grown health solutions.

Immutep (ASX:IMM) has announced positive results from a Phase 2b trial of its eftilagimod alfa (efti) in combination with MSD's KEYTRUDA (pembrolizumab) for head and neck cancer.

AusBiotech has signed a partnership agreement with digital health commercialisation specialist ANDHealth to enhance collaboration on mutual interests and support ongoing industry innovation.

Alterity Therapeutics (ASX:ATH) has announced that the US FDA has granted fast track designation for ATH434 for treating Multiple System Atrophy.

Neurotech International (ASX:NTI) has announced positive results from its recently completed 28-day Good Laboratory Practice oral toxicology studies evaluating its lead drug candidate NTI164.

Arovella Therapeutics (ASX:ALA) has entered into an exclusive option to license multiple patent families from Baylor College of Medicine to broaden the utility and enhance the performance of its iNKT cell platform.

In one of the largest licensing deals in the Australian biotechnology industry, Dimerix (ASX:DXB) has signed an exclusive US licence agreement with Amicus Therapeutics to commercialise its kidney disease drug candidate DMX-200.

Race Oncology (ASX:RAC) has announced the successful and safe dosing of the first patient with RC220 in its Phase 1 clinical trial in advanced solid tumours.

Cell therapy company AdAlta (ASX:1AD) is undertaking a two-for-three renounceable rights issue at 0.3 cents per share to raise up to approximately $1.3 million.